Transcription Factor HBP1 Enhances Radiosensitivity by Inducing Apoptosis in Prostate Cancer Cell Lines

Overview

Journal Anal Cell Pathol (Amst)

Specialties Cell Biology
Oncology
Pathology

Date 2016 Mar 5

PMID 26942107

Citations 7

Authors

Yicheng Chen

Yueping Wang

Yanlan Yu

Liwei Xu

Youyun Zhang

Shicheng Yu

Gonghui Li

Zhigeng Zhang

Affiliations

Soon will be listed here.

Abstract

Radiotherapy for prostate cancer has been gradually carried out in recent years; however, acquired radioresistance often occurred in some patients after radiotherapy. HBP1 (HMG-box transcription factor 1) is a transcriptional inhibitor which could inhibit the expression of dozens of oncogenes. In our previous study, we showed that the expression level of HBP1 was closely related to prostate cancer metastasis and prognosis, but the relationship between HBP1 and radioresistance for prostate cancer is largely unknown. In this study, the clinical data of patients with prostate cancer was compared, and the positive correlation was revealed between prostate cancer brachytherapy efficacy and the expression level of HBP1 gene. Through research on prostate cancer cells in vitro, we found that HBP1 expression levels were negatively correlated with oncogene expression levels. Furthermore, HBP1 overexpression could sensitize prostate cancer cells to radiation and increase apoptosis in prostate cancer cells. In addition, animal model was employed to analyze the relationship between HBP1 gene and prostate cancer radiosensitivity in vivo; the result showed that knockdown of HBP1 gene could decrease the sensitivity to radiation of xenograft. These studies identified a specific molecular mechanism underlying prostate cancer radiosensitivity, which suggested HBP1 as a novel target in prostate cancer radiotherapy.

Citing Articles

Alakhdar A, Sivakumar S, Kopchak R, Hunter A, Ambrosio F, Washburn N Adv Biol (Weinh). 2024; 8(12):e2400334.

PMID: 39601528 PMC: 11889993. DOI: 10.1002/adbi.202400334.

Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients.

Jost T, Schuster B, Heinzerling L, Weissmann T, Fietkau R, Distel L Strahlenther Onkol. 2022; 198(9):838-848.

PMID: 35471558 PMC: 9402507. DOI: 10.1007/s00066-022-01945-y.

Epigenetic mechanisms underlying prostate cancer radioresistance.

Macedo-Silva C, Benedetti R, Ciardiello F, Cappabianca S, Jeronimo C, Altucci L Clin Epigenetics. 2021; 13(1):125.

PMID: 34103085 PMC: 8186094. DOI: 10.1186/s13148-021-01111-8.

Long noncoding RNA actin filament-associated protein 1 antisense RNA 1 promotes malignant phenotype through binding with lysine-specific demethylase 1 and repressing HMG box-containing protein 1 in non-small-cell lung cancer.

Yu S, Yang D, Ye Y, Liu P, Chen Z, Lei T Cancer Sci. 2019; 110(7):2211-2225.

PMID: 31069893 PMC: 6609801. DOI: 10.1111/cas.14039.

The HMG box transcription factor HBP1: a cell cycle inhibitor at the crossroads of cancer signaling pathways.

Bollaert E, de Rocca Serra A, Demoulin J Cell Mol Life Sci. 2019; 76(8):1529-1539.

PMID: 30683982 PMC: 11105191. DOI: 10.1007/s00018-019-03012-9.

References

Yee A, Paulson E, McDevitt M, Rieger-Christ K, Summerhayes I, Berasi S . The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression. Gene. 2004; 336(1):1-13. DOI: 10.1016/j.gene.2004.04.004. View

Hassan M, Khattouti A, Ejaeidi A, Ma T, Day W, Espinoza I . Elevated Expression of Hepatoma Up-Regulated Protein Inhibits γ-Irradiation-Induced Apoptosis of Prostate Cancer Cells. J Cell Biochem. 2015; 117(6):1308-18. DOI: 10.1002/jcb.25419. View

Sun X, Geng X, Zhang J, Zhao H, Liu Y . miR-155 promotes the growth of osteosarcoma in a HBP1-dependent mechanism. Mol Cell Biochem. 2015; 403(1-2):139-47. DOI: 10.1007/s11010-015-2344-z. View

Watanabe N, Kageyama R, Ohtsuka T . Hbp1 regulates the timing of neuronal differentiation during cortical development by controlling cell cycle progression. Development. 2015; 142(13):2278-90. DOI: 10.1242/dev.120477. View

Koff J, Ramachandiran S, Bernal-Mizrachi L . A time to kill: targeting apoptosis in cancer. Int J Mol Sci. 2015; 16(2):2942-55. PMC: 4346874. DOI: 10.3390/ijms16022942. View

Chang L, Graham P, Ni J, Hao J, Bucci J, Cozzi P . Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol. 2015; 96(3):507-17. DOI: 10.1016/j.critrevonc.2015.07.005. View

Zhu X, Zhao H, Lin Z, Zhang G . Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia. Cancer Gene Ther. 2015; 22(12):573-80. DOI: 10.1038/cgt.2015.50. View

Fried N, Burnett A . Novel methods for mapping the cavernous nerves during radical prostatectomy. Nat Rev Urol. 2015; 12(8):451-60. DOI: 10.1038/nrurol.2015.174. View

Torrecilla J, Hervas A, Zapatero A, Gomez Caamano A, Macias V, Herruzo I . Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance. Rep Pract Oncol Radiother. 2015; 20(4):259-72. PMC: 4477122. DOI: 10.1016/j.rpor.2015.04.003. View

10.

Wiedemuth R, Klink B, Topfer K, Schrock E, Schackert G, Tatsuka M . Survivin safeguards chromosome numbers and protects from aneuploidy independently from p53. Mol Cancer. 2014; 13:107. PMC: 4041913. DOI: 10.1186/1476-4598-13-107. View

11.

Indovina P, Pentimalli F, Casini N, Vocca I, Giordano A . RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget. 2015; 6(20):17873-90. PMC: 4627222. DOI: 10.18632/oncotarget.4286. View

12.

Albert M, Song J, Schultz D, Cormack R, Tempany C, Haker S . Defining the rectal dose constraint for permanent radioactive seed implantation of the prostate. Urol Oncol. 2008; 26(2):147-52. DOI: 10.1016/j.urolonc.2007.03.026. View

13.

Berasi S, Xiu M, Yee A, Paulson K . HBP1 repression of the p47phox gene: cell cycle regulation via the NADPH oxidase. Mol Cell Biol. 2004; 24(7):3011-24. PMC: 371097. DOI: 10.1128/MCB.24.7.3011-3024.2004. View

14.

Ohashi A, Ohori M, Iwai K, Nakayama Y, Nambu T, Morishita D . Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat Commun. 2015; 6:7668. PMC: 4506520. DOI: 10.1038/ncomms8668. View

15.

Goldar S, Shekari Khaniani M, Mansoori Derakhshan S, Baradaran B . Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015; 16(6):2129-44. DOI: 10.7314/apjcp.2015.16.6.2129. View

16.

Katzenwadel A, Wolf P . Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. Cancer Lett. 2015; 367(1):12-7. DOI: 10.1016/j.canlet.2015.06.021. View

17.

Alshatwi A, Subash-Babu P, Antonisamy P . Violacein induces apoptosis in human breast cancer cells through up regulation of BAX, p53 and down regulation of MDM2. Exp Toxicol Pathol. 2015; 68(1):89-97. DOI: 10.1016/j.etp.2015.10.002. View

18.

Shalini S, Dorstyn L, Dawar S, Kumar S . Old, new and emerging functions of caspases. Cell Death Differ. 2014; 22(4):526-39. PMC: 4356345. DOI: 10.1038/cdd.2014.216. View

19.

Lei J, Liu L, Wei Q, Yan S, Song T, Lin F . Systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer. Sci Rep. 2015; 5:7713. PMC: 5378991. DOI: 10.1038/srep07713. View

20.

Bjurlin M, Rosenkrantz A, Beltran L, Raad R, Taneja S . Imaging and evaluation of patients with high-risk prostate cancer. Nat Rev Urol. 2015; 12(11):617-28. DOI: 10.1038/nrurol.2015.242. View